{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:50:32Z","timestamp":1793364632003,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1245\/s10434-026-19630-0","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T16:13:16Z","timestamp":1776615196000},"page":"7169-7180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Axillary Pathologic Complete Response as a Stronger Prognostic Marker than Breast pCR in Clinically Node-Positive Stage II\u2013III Breast Cancer"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-9662","authenticated-orcid":false,"given":"Serdar","family":"Sar\u0131demir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur Can","family":"G\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Din\u00e7er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Karayi\u011fit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihangir","family":"\u00d6zaslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"issue":"5","key":"19630_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(5):331\u201357. https:\/\/doi.org\/10.6004\/jnccn.2024.0035.","journal-title":"J Natl Compr Canc Netw."},{"issue":"9938","key":"19630_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"Lancet."},{"issue":"15","key":"19630_CR3","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796\u2013804. https:\/\/doi.org\/10.1200\/JCO.2011.38.8595.","journal-title":"J Clin Oncol."},{"issue":"12","key":"19630_CR4","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3492.","journal-title":"Clin Cancer Res."},{"key":"19630_CR5","doi-asserted-by":"publisher","first-page":"1093155","DOI":"10.3389\/fonc.2023.1093155","volume":"13","author":"X Ren","year":"2023","unstructured":"Ren X, Liu C, Wang J, et al. Axillary response and outcome in breast cancer patients receiving neoadjuvant treatment. Front Oncol. 2023;13:1093155. https:\/\/doi.org\/10.3389\/fonc.2023.1093155.","journal-title":"Front Oncol."},{"issue":"4","key":"19630_CR6","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","volume":"260","author":"JC Boughey","year":"2014","unstructured":"Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260(4):608\u201314. https:\/\/doi.org\/10.1097\/SLA.0000000000000924.","journal-title":"Ann Surg."},{"issue":"25","key":"19630_CR7","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","volume":"29","author":"M Untch","year":"2011","unstructured":"Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in HER2-overexpressing breast cancer: results from the TECHNO trial. J Clin Oncol. 2011;29(25):3351\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.31.4930.","journal-title":"J Clin Oncol."},{"issue":"17","key":"19630_CR8","doi-asserted-by":"publisher","first-page":"5197","DOI":"10.7150\/jca.51021","volume":"12","author":"SC Chen","year":"2021","unstructured":"Chen SC, Chiu CH, Chen MF, et al. Discrepancy between pathological complete response in breast and axillary lymph nodes after neoadjuvant chemotherapy for breast cancer: analysis of subgroup clinicopathological factors. J Cancer. 2021;12(17):5197\u2013205. https:\/\/doi.org\/10.7150\/jca.51021.","journal-title":"J Cancer."},{"issue":"13","key":"19630_CR9","doi-asserted-by":"publisher","first-page":"8302","DOI":"10.1245\/s10434-023-14082-2","volume":"30","author":"R Flores","year":"2023","unstructured":"Flores R, Roldan E, Pardo JA, et al. Discordant breast and axillary pathologic response to neoadjuvant chemotherapy. Ann Surg Oncol. 2023;30(13):8302\u20137. https:\/\/doi.org\/10.1245\/s10434-023-14082-2.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"19630_CR10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","volume":"268","author":"OM Fayanju","year":"2018","unstructured":"Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018;268(4):591\u2013601. https:\/\/doi.org\/10.1097\/SLA.0000000000002953.","journal-title":"Ann Surg."},{"issue":"4","key":"19630_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaoncol.2015.4935","volume":"2","author":"SS Mougalian","year":"2016","unstructured":"Mougalian SS, Hernandez M, Lei X, et al. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol. 2016;2(4):508\u201316. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4935.","journal-title":"JAMA Oncol."},{"key":"19630_CR12","unstructured":"Amin MB, Edge SB, Greene FL, et al. (eds). AJCC cancer staging manual. 8th edn. Springer; 2017."},{"issue":"5","key":"19630_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. Arch Pathol Lab Med. 2020;144(5):545\u201363. https:\/\/doi.org\/10.5858\/arpa.2019-0904-SA.","journal-title":"Arch Pathol Lab Med."},{"issue":"22","key":"19630_CR14","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.23.00674","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2023;41(22):3867\u201372. https:\/\/doi.org\/10.1200\/JCO.23.00674.","journal-title":"J Clin Oncol."},{"issue":"20","key":"19630_CR15","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\/CAP clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol."},{"issue":"8","key":"19630_CR16","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736\u201347. https:\/\/doi.org\/10.1093\/annonc\/mdr304.","journal-title":"Ann Oncol."},{"issue":"10","key":"19630_CR17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2021. Ann Oncol. 2021;32(10):1216\u201335. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.023.","journal-title":"Ann Oncol."},{"issue":"24","key":"19630_CR18","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1200\/JCO.20.03613","volume":"39","author":"SM Tolaney","year":"2021","unstructured":"Tolaney SM, Garrett-Mayer E, White J, et al. Updated Standardized Definitions for Efficacy End Points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J Clin Oncol. 2021;39(24):2720\u201331. https:\/\/doi.org\/10.1200\/JCO.20.03613.","journal-title":"J Clin Oncol."},{"issue":"7","key":"19630_CR19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021;113(7):808\u201319. https:\/\/doi.org\/10.1093\/jnci\/djaa201.","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"19630_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0397","volume":"156","author":"S Samiei","year":"2021","unstructured":"Samiei S, Simons JM, Engelen SME, et al. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg. 2021;156(6):e210397. https:\/\/doi.org\/10.1001\/jamasurg.2021.0397.","journal-title":"JAMA Surg."},{"issue":"5","key":"19630_CR21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/bjs.11939","volume":"108","author":"L Zetterlund","year":"2021","unstructured":"Zetterlund L, Celebioglu F, Frisell J, et al. Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status. Br J Surg. 2021;108(5):583\u201391. https:\/\/doi.org\/10.1002\/bjs.11939.","journal-title":"Br J Surg."},{"issue":"3","key":"19630_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen B, Fong C, Luthra A, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022;185(3):563-75.e11. https:\/\/doi.org\/10.1016\/j.cell.2022.01.003.","journal-title":"Cell."},{"issue":"6","key":"19630_CR23","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","volume":"174","author":"L Keren","year":"2018","unstructured":"Keren L, Bosse M, Marquez D, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018;174(6):1373-87.e19. https:\/\/doi.org\/10.1016\/j.cell.2018.08.039.","journal-title":"Cell."},{"issue":"11","key":"19630_CR24","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.cell.2022.04.026","volume":"185","author":"NE Reticker-Flynn","year":"2022","unstructured":"Reticker-Flynn NE, Zhang W, Belk JA, et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell. 2022;185(11):1924-42.e23. https:\/\/doi.org\/10.1016\/j.cell.2022.04.026.","journal-title":"Cell."},{"issue":"28","key":"19630_CR25","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414\u201322. https:\/\/doi.org\/10.1200\/JCO.2007.10.6823.","journal-title":"J Clin Oncol."},{"issue":"2","key":"19630_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis. Lancet Oncol. 2022;23(2):149\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(21)00589-1.","journal-title":"Lancet Oncol."},{"issue":"26","key":"19630_CR27","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1200\/JCO.2011.39.2779","volume":"30","author":"LJ Esserman","year":"2012","unstructured":"Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 trial. J Clin Oncol. 2012;30(26):3242\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.39.2779.","journal-title":"J Clin Oncol."},{"key":"19630_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2022.12.020","volume":"181","author":"P Nuciforo","year":"2023","unstructured":"Nuciforo P, Radosevic-Robin N, Ng T, et al. Ten-year follow-up of pathologic complete responders in NeoALTTO: a multicenter randomized trial of neoadjuvant lapatinib and\/or trastuzumab plus paclitaxel. Eur J Cancer. 2023;181:92\u2013101. https:\/\/doi.org\/10.1016\/j.ejca.2022.12.020.","journal-title":"Eur J Cancer."},{"issue":"14","key":"19630_CR29","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA."},{"issue":"7","key":"19630_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9.","journal-title":"Lancet Oncol."},{"issue":"10","key":"19630_CR31","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: targeted axillary dissection. J Clin Oncol. 2016;34(10):1072\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094.","journal-title":"J Clin Oncol."},{"issue":"22","key":"19630_CR32","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med."},{"issue":"7","key":"19630_CR33","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med."},{"key":"19630_CR34","unstructured":"U.S. Food and Drug Administration. Guidance for industry: pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: Use as an endpoint to support accelerated approval. FDA; 2020."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19630-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19630-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19630-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:41:07Z","timestamp":1783345267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19630-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["19630"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19630-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital (Approval No. 2025-02\/22).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The requirement for informed consent was waived due to the retrospective design and the use of routinely collected, anonymized clinical data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}